Twist Bioscience Ownership
| TWST Stock | USD 43.62 0.99 2.22% |
Shares in Circulation | First Issued 2017-09-30 | Previous Quarter 58.1 M | Current Value 58.6 M | Avarage Shares Outstanding 42.7 M | Quarterly Volatility 14.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Twist |
Twist Stock Ownership Analysis
About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.6. Twist Bioscience Corp had not issued any dividends in recent years. Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Twist Bioscience operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 989 people. To find out more about Twist Bioscience Corp contact Emily Leproust at 800 719 0671 or learn more at https://www.twistbioscience.com.Besides selling stocks to institutional investors, Twist Bioscience also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Twist Bioscience's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Twist Bioscience's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Twist Bioscience Quarterly Liabilities And Stockholders Equity |
|
Twist Bioscience Insider Trades History
Only 1.94% of Twist Bioscience Corp are currently held by insiders. Unlike Twist Bioscience's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Twist Bioscience's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Twist Bioscience's insider trades
Twist Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Twist Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Twist Bioscience Corp backward and forwards among themselves. Twist Bioscience's institutional investor refers to the entity that pools money to purchase Twist Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 991.1 K | Thrivent Financial For Lutherans | 2024-09-30 | 973.7 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 962.2 K | Goldman Sachs Group Inc | 2024-09-30 | 921.4 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 880.2 K | Baillie Gifford & Co Limited. | 2024-09-30 | 834.3 K | Tao Capital Management Lp | 2024-09-30 | 828.8 K | Wellington Management Company Llp | 2024-09-30 | 797.7 K | Artisan Partners Limited Partnership | 2024-09-30 | 6 M | Vanguard Group Inc | 2024-09-30 | 5.6 M |
Twist Bioscience Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Twist Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Twist Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Twist Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Twist Bioscience Outstanding Bonds
Twist Bioscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Twist Bioscience Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Twist bonds can be classified according to their maturity, which is the date when Twist Bioscience Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Twist Bioscience Corporate Filings
F4 | 18th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 15th of November 2024 Other Reports | ViewVerify | |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.